Journal
MUSCLE & NERVE
Volume 44, Issue 2, Pages 160-169Publisher
WILEY
DOI: 10.1002/mus.22090
Keywords
CUGBP1; DM1; MBNL1; myotonia; myotonic dystrophy
Categories
Funding
- NIAMS [RO1AR052771, RO1AR045992]
- Muscular Dystrophy Association
- NINDS Research Education Program [R25 NS065733]
Ask authors/readers for more resources
Myotonic dystrophy (DM1), the most common adult muscular dystrophy, is a multisystem, autosomal dominant genetic disorder caused by an expanded CTG repeat that leads to nuclear retention of a mutant RNA and subsequent RNA toxicity. Significant insights into the molecular mechanisms of RNA toxicity have led to the previously unforeseen possibility that treating DM1 is a viable prospect. In this review, we briefly present the clinical picture in DM1, and describe how the research in understanding the pathogenesis of RNA toxicity in DM1 has led to targeted approaches to therapeutic development at various steps in the pathogenesis of the disease. We discuss the promise and current limitations of each with an emphasis on RNA-based therapeutics and small molecules. We conclude with a discussion of the unmet need for clinical tools and outcome measures that are essential prerequisites to proceed in evaluating these potential therapies in clinical trials. Muscle Nerve 44: 160-169, 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available